These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 18844671)

  • 1. Development of a new pharmacophore model that discriminates active compstatin analogs.
    Chiu TL; Mulakala C; Lambris JD; Kaznessis YN
    Chem Biol Drug Des; 2008 Oct; 72(4):249-56. PubMed ID: 18844671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational analysis of complement inhibitor compstatin using molecular dynamics.
    Devaurs D; Antunes DA; Kavraki LE
    J Mol Model; 2020 Aug; 26(9):231. PubMed ID: 32789582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-kinetic relationship analysis of the therapeutic complement inhibitor compstatin.
    Magotti P; Ricklin D; Qu H; Wu YQ; Kaznessis YN; Lambris JD
    J Mol Recognit; 2009; 22(6):495-505. PubMed ID: 19658192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C3 activation is inhibited by analogs of compstatin but not by serine protease inhibitors or peptidyl alpha-ketoheterocycles.
    Furlong ST; Dutta AS; Coath MM; Gormley JJ; Hubbs SJ; Lloyd D; Mauger RC; Strimpler AM; Sylvester MA; Scott CW; Edwards PD
    Immunopharmacology; 2000 Jul; 48(2):199-212. PubMed ID: 10936517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding kinetics, structure-activity relationship, and biotransformation of the complement inhibitor compstatin.
    Sahu A; Soulika AM; Morikis D; Spruce L; Moore WT; Lambris JD
    J Immunol; 2000 Sep; 165(5):2491-9. PubMed ID: 10946275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies of structure-activity relations of complement inhibitor compstatin.
    Soulika AM; Morikis D; Sarrias MR; Roy M; Spruce LA; Sahu A; Lambris JD
    J Immunol; 2003 Aug; 171(4):1881-90. PubMed ID: 12902490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compstatin inhibits complement activation by binding to the beta-chain of complement factor 3.
    Soulika AM; Holland MC; Sfyroera G; Sahu A; Lambris JD
    Mol Immunol; 2006 May; 43(12):2023-9. PubMed ID: 16472861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Solution structure of Compstatin, a potent complement inhibitor.
    Morikis D; Assa-Munt N; Sahu A; Lambris JD
    Protein Sci; 1998 Mar; 7(3):619-27. PubMed ID: 9541394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and NMR characterization of active analogues of compstatin containing non-natural amino acids.
    Mallik B; Katragadda M; Spruce LA; Carafides C; Tsokos CG; Morikis D; Lambris JD
    J Med Chem; 2005 Jan; 48(1):274-86. PubMed ID: 15634022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin.
    Katragadda M; Magotti P; Sfyroera G; Lambris JD
    J Med Chem; 2006 Jul; 49(15):4616-22. PubMed ID: 16854067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thermodynamic studies on the interaction of the third complement component and its inhibitor, compstatin.
    Katragadda M; Morikis D; Lambris JD
    J Biol Chem; 2004 Dec; 279(53):54987-95. PubMed ID: 15489226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The structural basis of compstatin activity examined by structure-function-based design of peptide analogs and NMR.
    Morikis D; Roy M; Sahu A; Troganis A; Jennings PA; Tsokos GC; Lambris JD
    J Biol Chem; 2002 Apr; 277(17):14942-53. PubMed ID: 11847226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition.
    Janssen BJ; Halff EF; Lambris JD; Gros P
    J Biol Chem; 2007 Oct; 282(40):29241-7. PubMed ID: 17684013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Species specificity of the complement inhibitor compstatin investigated by all-atom molecular dynamics simulations.
    Tamamis P; Morikis D; Floudas CA; Archontis G
    Proteins; 2010 Sep; 78(12):2655-67. PubMed ID: 20589629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular dynamics in drug design: new generations of compstatin analogs.
    Tamamis P; López de Victoria A; Gorham RD; Bellows-Peterson ML; Pierou P; Floudas CA; Morikis D; Archontis G
    Chem Biol Drug Des; 2012 May; 79(5):703-18. PubMed ID: 22233517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new generation of potent complement inhibitors of the Compstatin family.
    López de Victoria A; Gorham RD; Bellows-Peterson ML; Ling J; Lo DD; Floudas CA; Morikis D
    Chem Biol Drug Des; 2011 Jun; 77(6):431-40. PubMed ID: 21352502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3.
    Sahu A; Morikis D; Lambris JD
    Mol Immunol; 2003 Jan; 39(10):557-66. PubMed ID: 12431389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conformational analysis of compstatin analogues with molecular dynamics simulations in explicit water.
    Tamamis P; Skourtis SS; Morikis D; Lambris JD; Archontis G
    J Mol Graph Model; 2007 Sep; 26(2):571-80. PubMed ID: 17498990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Analogs of the Complement C3 Inhibitor Compstatin with Increased Solubility and Improved Pharmacokinetic Profile.
    Berger N; Alayi TD; Resuello RRG; Tuplano JV; Reis ES; Lambris JD
    J Med Chem; 2018 Jul; 61(14):6153-6162. PubMed ID: 29920096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A simple, yet highly accurate, QSAR model captures the complement inhibitory activity of compstatin.
    Mulakala C; Lambris JD; Kaznessis Y
    Bioorg Med Chem; 2007 Feb; 15(4):1638-44. PubMed ID: 17188878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.